A piece of history.
D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D001249:Asthma / Q000188:drug therapy*; D001709:Biotechnology / Q000379:methods* / Q000639:trends*; D002986:Clinical Trials as Topic; D017277:Drug Approval / Q000379:methods; D004353:Drug Evaluation, Preclinical / Q000379:methods* / Q000639:trends; D005544:Forecasting; D006801:Humans; D000069444:Omalizumab; D012106:Research / Q000639:trends*; D014481:United States; D014486:United States Food and Drug Administration
D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000069444:Omalizumab